Verrax J, Calderon P Buc
Unité de Pharmacocinétique, Métabolisme, Nutrition, et Toxicologie (PMNT), Département des sciences pharmaceutiques, Université Catholique de Louvain, Brussels, Belgium.
Biochem Pharmacol. 2008 Dec 15;76(12):1644-52. doi: 10.1016/j.bcp.2008.09.024. Epub 2008 Sep 30.
In 2008, we celebrate the 80th anniversary of the discovery of vitamin C. Since then, we know that vitamin C possesses few pharmacological actions although it is still perceived by the public as a "miracle-pill" capable to heal a variety of illnesses. Cancer is one of the most common diseases for which a beneficial role of vitamin C has been claimed. Thus, its dietary use has been proposed in cancer prevention for several years. Apart from this nutritional aspect, an extensive and often confusing literature exists about the use of vitamin C in cancer that has considerably discredited its use. Nevertheless, recent pharmacokinetic data suggest that pharmacologic concentrations of vitamin C can be achieved by intravenous injections. Since these concentrations exhibit anticancer activities in vitro, this raises the controversial question of the re-evaluation of vitamin C in cancer treatment. Therefore, the purpose of this commentary is to make a critical review of our current knowledge of vitamin C, focusing on the rationale that could support its use in cancer therapy.
2008年，我们迎来了维生素C发现80周年。从那时起，我们知道维生素C几乎没有药理作用，尽管它在公众眼中仍被视为一种能治愈各种疾病的“神奇药丸”。癌症是人们声称维生素C具有有益作用的最常见疾病之一。因此，多年来一直有人提议在癌症预防中使用维生素C。除了这一营养方面，关于维生素C在癌症中的应用存在大量且常常令人困惑的文献，这使得其应用备受质疑。然而，最近的药代动力学数据表明，通过静脉注射可以达到维生素C的药理浓度。由于这些浓度在体外表现出抗癌活性，这就引发了在癌症治疗中重新评估维生素C这一有争议的问题。因此，本评论的目的是对我们目前关于维生素C的知识进行批判性回顾，重点关注支持其在癌症治疗中应用的理论依据。
